{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:17:03Z","timestamp":1788225423843,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.isci.2026.116509","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:35:38Z","timestamp":1782300938000},"page":"116509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Mahnoor","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-9169","authenticated-orcid":false,"given":"Anisha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116509_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2023.103920","article-title":"An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities","volume":"31","author":"Abduh","year":"2024","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.isci.2026.116509_bib2","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/cancers13102326","article-title":"The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology","volume":"13","author":"Fan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.116509_bib3","article-title":"Targeting BCMA in multiple myeloma: A comprehensive review of immunotherapeutic strategies and clinical outcomes","volume":"33","author":"Chan","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib4","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116509_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2026.116509_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib7","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.isci.2026.116509_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.isci.2026.116509_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T Cell Performance: How to Improve Their Persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib11","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.116509_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41419-023-05727-x","article-title":"Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells","volume":"14","author":"Pourzia","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.116509_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med. (Lond.)"},{"key":"10.1016\/j.isci.2026.116509_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1719391","article-title":"Autoimmune disease-associated lymphomas: research progress and review","volume":"16","author":"Chen","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib15","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/cells13181596","article-title":"Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia","volume":"13","author":"Bartoszewska","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.116509_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.isci.2026.116509_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.isci.2026.116509_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.isci.2026.116509_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.116509_bib21","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116509_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1558275","article-title":"Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias","volume":"16","author":"Morgan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103267","article-title":"Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis","volume":"84","author":"Zhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.isci.2026.116509_bib24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/03007995.2024.2391112","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison","volume":"40","author":"Bar","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.isci.2026.116509_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib26","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jtct.2025.12.057","article-title":"KarMMa-3 Subgroup Analysis in Older Patients with Relapsed\/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel","volume":"32","author":"Ailawadhi","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.116509_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1455464","article-title":"Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed\/refractory multiple myeloma","volume":"14","author":"Hamadeh","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41408-024-01120-9","article-title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","volume":"14","author":"Joseph","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.116509_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib31","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116509_bib32","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.isci.2026.116509_bib33","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/ajh.70002","article-title":"Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?","volume":"100","author":"Mian","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2026.116509_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10238-024-01442-9","article-title":"Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy","volume":"24","author":"Rehman","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.isci.2026.116509_bib35","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116509_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.116509_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.116509_bib38","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116509_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1592377","article-title":"Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology","volume":"16","author":"Ershova","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.iotech.2020.09.001","article-title":"Function and evolution of the prototypic CD28\u03b6 and 4-1BB\u03b6 chimeric antigen receptors","volume":"8","author":"Feucht","year":"2020","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.isci.2026.116509_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1613222","article-title":"Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma","volume":"16","author":"Moares","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970380.84060.bf","article-title":"P869: Updated Results of a Phase I, Open-Label Study of Bcma\/Cd19 Dual-Targeting Fastcar-T Gc012f for Patients with Relapsed\/Refractory Multiple Myeloma (Rrmm)","volume":"7","author":"Du","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.116509_bib43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib45","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.isci.2026.116509_bib46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Therapeutic Advances in Hematology"},{"key":"10.1016\/j.isci.2026.116509_bib47","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/cells8121632","article-title":"CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents","volume":"8","author":"Costa","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.116509_bib48","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116509_bib49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40264-025-01538-5","article-title":"Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients","volume":"48","author":"Renninger","year":"2025","journal-title":"Drug Saf."},{"key":"10.1016\/j.isci.2026.116509_bib50","first-page":"21","article-title":"CAR T-Cell Therapy: Adverse Events and Management","volume":"10","author":"Adkins","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib51","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/curroncol32040198","article-title":"Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations","volume":"32","author":"Arvanitis","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2026.116509_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib54","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2025.01.884","article-title":"Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy","volume":"31","author":"Maillie","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.isci.2026.116509_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T Cell Toxicity: Current Management and Future Directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.116509_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1398879","article-title":"Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.116509_bib57","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.116509_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.116509_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.116509_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.isci.2026.116509_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1368732","article-title":"Prospects and challenges of CAR-T cell therapy combined with ICIs","volume":"14","author":"Lv","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.116509_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116509_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-025-00736-8","article-title":"Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases","volume":"13","author":"Huang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2026.116509_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/09636897251374203","article-title":"Correlation between the expression of soluble BCMA and short-term\/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma","volume":"34","author":"Fu","year":"2025","journal-title":"Cell Transplant."},{"key":"10.1016\/j.isci.2026.116509_bib68","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1097\/MS9.0000000000001375","article-title":"Toxicities of CAR T-cell therapy: a review of current literature","volume":"85","author":"Asghar","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.isci.2026.116509_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: Focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.isci.2026.116509_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2025.2483613","article-title":"CAR-T cell therapies: patient access and affordability solutions","volume":"11","author":"Gon\u00e7alves","year":"2025","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.isci.2026.116509_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100026","article-title":"Broadening CAR-T access: lessons from real-world implementation of talicabtagene autoleucel in India","volume":"2","author":"Purwar","year":"2026","journal-title":"Blood Immunology & Cellular Therapy"},{"key":"10.1016\/j.isci.2026.116509_bib72","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226018845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226018845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:12:08Z","timestamp":1788225128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226018845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589004226018845"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116509","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116509"}}